Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(14%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_1
2
29%
Ph not_applicable
2
29%
Ph phase_2
1
14%
Ph phase_4
2
29%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 4Post-market surveillance
2(28.6%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 42 (28.6%)
N/A2 (28.6%)

Trials by Status

recruiting114%
completed686%

Recent Activity

1 active trials
Showing 5 of 7
recruitingnot_applicable

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

NCT07294547
completednot_applicable

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

NCT00400322
completedphase_4

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

NCT01376804
completedphase_1

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

NCT01165580
completedphase_4

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

NCT00431353
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07294547Not Applicable

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Recruiting
NCT00400322Not Applicable

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

Completed
NCT01376804Phase 4

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Completed
NCT01165580Phase 1

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

Completed
NCT00431353Phase 4

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

Completed
NCT00090766Phase 2

A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Completed
NCT00377741Phase 1

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7